Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817752 · ClinicalTrials.gov registry record · Phase 1
Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation
A Phase 1 study, sponsored by National University of Natural Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00817752: Completed Phase 1 study, sponsored by National University of Natural Medicine.
NCT00817752 is a Phase 1 study that has completed, run by National University of Natural Medicine. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00817752, a Phase 1 study, has completed, sponsored by National University of Natural Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Ayurvedic medicine has been practiced in for more than 2,500 years. Ashwagandha is one of the most widely utilized herbs in the system. It is thought to affect the endocrine, immune, nervous, and cardiopulmonary systems. This study is designed as a preliminary investigation of the effects of Ashwagandha on stress, inflammation, and immune modulation. Participants will take the liquid extract in cow's milk twice a day for five days. The results of initial, one-day, and final blood draws will be compared to determine participant's beginning and ending levels of cortisol, inflammatory cytokines, and immune-cell activation (CD4 T-cells, CD8 T-cells, B cells and natural killer cells). Measurements will be completed using flow cytometry and ELISA assay. The purpose of this study is to determine which effects of Ashwagandha are most suitable for further investigation.
Interventions
- DIETARY_SUPPLEMENT Ashwagandha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
What the finished NCT00817752 record still lists
NCT00817752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Ashwagandha is the first listed.
NCT00817752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00817752 about?
NCT00817752 is a clinical study titled "Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation". Ayurvedic medicine has been practiced in for more than 2,500 years. Ashwagandha is one of the most widely utilized herbs in the system. It is thought to affect the endocrine, immune, nervous, and cardiopulmonary systems. This study is designed as a preliminary investigation of the effects of Ashwaga...
What is the current status of trial NCT00817752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00817752?
The interventions under investigation include: Ashwagandha (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00817752?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00817752's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia